Lead Product(s) : Debio-1453
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $20.2 million
Deal Type : Funding
CARB-X Grants Debiopharm $12.3 Million To Advance Novel Antibiotic for Gonorrhea
Details : The grant will support the continued clinical development of Debio 1453, a first-in-class antibiotic with a novel mechanism of action to treat Neisseria gonorrhoeae infections.
Product Name : Debio 1453
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 28, 2025
Lead Product(s) : Debio-1453
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $20.2 million
Deal Type : Funding
Lead Product(s) : Debio 1453
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Gardp
Deal Size : Undisclosed
Deal Type : Agreement
GARDP Supports Debiopharm’s Gonorrhoea Treatment Development
Details : Under the agreement, Debiopharm will advance the development of Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae.
Product Name : Debio 1453
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 14, 2025
Lead Product(s) : Debio 1453
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Gardp
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : BAL2420
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $7.3 million
Deal Type : Funding
Basilea Receives CARB-X Funding to Develop Novel Antibiotics Candidate
Details : The funding will support the progression of Basilea’s novel antibiotic candidate BAL2420 LptA inhibitor for the treating Infectious Diseases.
Product Name : BAL2420
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 23, 2024
Lead Product(s) : BAL2420
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $7.3 million
Deal Type : Funding
Lead Product(s) : LBT-SA7
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LimmaTech Awarded FDA Fast Track Designation for Staphylococcus aureus Vaccine
Details : LBT-SA7 is a multivalent toxoid vaccine candidate, which is designed to prevent skin and soft tissue infections caused by the bacterial pathogen, Staphylococcus aureus.
Product Name : LBT-SA7
Product Type : Vaccine
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : LBT-SA7
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 1453
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $5.7 million
Deal Type : Funding
CARB-X Funds Debiopharm for Antibiotics Against Drug-Resistant Gonorrhoeae
Details : The funding will support the preclinical development of Debio 1453, a novel antibiotic specifically designed to combat Neisseria gonorrhoeae infections.
Product Name : Debio 1453
Product Type : Antibiotic
Upfront Cash : Undisclosed
November 21, 2024
Lead Product(s) : Debio 1453
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $5.7 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $0.9 million
Deal Type : Funding
Basilea Awarded CARB-X Grant to Develop Recently Acquired Novel Class of Antibiotics
Details : Funding will support clinical development of first-in-class antibiotics targeting severe infections, particularly those caused by E. coli and K. pneumoniae.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $0.9 million
Deal Type : Funding
Lead Product(s) : RVX-sCPD9
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Rocketvax Collaborates with NIH for Clinical Trial of RVX-sCPD9 Candidate
Details : Through the collaboration, Rocketvax aims to focus on developing the next-generation live-attenuated viral vaccine RVX-sCPD9, which is being evaluated for the treatment of COVID-19.
Product Name : RVX-sCPD9
Product Type : Vaccine
Upfront Cash : Undisclosed
June 13, 2024
Lead Product(s) : RVX-sCPD9
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Basilea Pharmaceutica
Deal Size : $2.3 million
Deal Type : Acquisition
Basilea Announces Acquisition of Preclinical Antibiotics Program from Spexis
Details : Through the acquisition, Basilea gains a preclinical program of antibiotics from a novel class, targeting Gram-negative bacteria, including multidrug-resistant strains.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 15, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Basilea Pharmaceutica
Deal Size : $2.3 million
Deal Type : Acquisition
Lead Product(s) : LMTB Gonococcal Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Adjuvant Capital
Deal Size : $37.0 million
Deal Type : Series A Financing
Details : The proceeds will advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates, including LMTB gonococcal vaccine, against bacterial infections, including programs addressing shigellosis and gonor...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 10, 2023
Lead Product(s) : LMTB Gonococcal Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Adjuvant Capital
Deal Size : $37.0 million
Deal Type : Series A Financing
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Med Patent Pool Signs with Aurobindo, Cipla & Viatris for Generic HIV Prevention Medicine
Details : ViiV Healthcare sublicence agreements with Aurobindo, Cipla and Viatris to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis.
Product Name : Apretude-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement